Intriguingly, combining 5-AZA with ruxolitinib (a JAK1/STAT3 inhibitor) could synergistically abrogate JAK1/STAT3 pathway in CAFs and potentiate CAF normalization in LC and HNSCC. This evidence concerns the gene JAK1 and head and neck squamous cell carcinoma.